Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Elastic NV (ESTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Elastic NV — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Elastic NV trades at $77.12 (market cap $7.94B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.7× Elastic NV's market cap, and Elastic NV is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ESTC | |
|---|---|---|
Market Cap | $29.60B | $7.94B |
Sector | Health | Technology |
52-Week High | $491.22 | $94.47 |
52-Week Low | $205.48 | $43.30 |
Enterprise Value | $27.56B | $7.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Elastic N.V. (ESTC) trades at $77.16, up 1.1% with a bullish technical outlook. The stock shows strong profitability with a 76.07% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include a collaboration with OpenAI and recognition as a leader in Gartner's Magic Quadrant for Observability Platforms. Institutional activity is mixed, with Amundi increasing its stake while BNY Mellon reduced its position.
The outlook is positive, supported by earnings momentum and strategic partnerships, but risks include high valuation multiples and a recent legal investigation. Analyst consensus is bullish with a $74.21 price target, though the current price exceeds this, indicating potential near-term consolidation. Revenue growth and AI integration present key opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →
